Latest filing published 03 May 2024 for Arcutis Biotherapeutics, Inc..
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Matthew Richard Moore: trading record in brief
All filings by Matthew Richard Moore on record concern Arcutis Biotherapeutics, Inc., in the capacity of senior executive. We count 13 filings; the first trade dates from 3 March 2022 and the latest from 2 May 2024.
On the market, this insider has only sold: 4 sales, €98k in total. Outside the open market, there are 9 share grants. Since January 2024: no purchases and 2 sales on the market.
The latest filing, published on 3 May 2024, reports an open-market sale of €38k in Arcutis Biotherapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Matthew Richard Moore
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 4,166 shares0Common StockSEC:0001787306-24-000072:0
- 3,468 shares@ US$11.121260.2% of flowCommon StockSEC:0001787306-24-000036:0
- 26,666 sharesCommon StockSEC:0001787306-24-000022:0
- 28,000 shares0Common StockSEC:0001787306-24-000004:0
- 1,589 shares@ US$15.817739.8% of flowCommon StockSEC:0001567619-23-004543:0
- 13,300 shares0Common StockSEC:0001567619-22-006491:0
6 of 6 declarations
